“We are at a pivotal moment in our company’s journey as we have entered the late clinical stages for both Alzheimer’s and Parkinson’s,” said Maria Maccecchini, Ph.D., Founder and CEO of Annovis Bio. “It is incredibly rewarding to see our work bring us here, once again supporting that our drug is efficacious and safe across both indications. At this meeting, we will present comprehensive data that further underscores buntanetap’s potential to address unmet needs for patients.”
Annovis Bio to Present Promising Data on ... - Cure Parkinson's
Annovis Bio to Present Promising Data on Buntanetap at AD/PD™ 2025
Written by
Farooqji
To view profiles and participate in discussions please or .
Read more about...
1 Reply
•
Not what you're looking for?
You may also like...
Annovis Bio Buntanetap
With the Buntanetap phase III trial dosing ending soon, I noticed that Annovis Bio stock is...
Annovis Bio Releases Promising Phase III Parkinson’s Data
https://www.globenewswire.com/news-release/2024/07/02/2907365/0/en/Annovis-Bio-Announces-New-Data-fr
Annovis Bio Buntanetap Interim Analysis of the Parkinson's Clinical Study
https://www.prnewswire.com/news-releases/annovis-bio-announces-two-presentations-at-the-adpd-2023-in
Annovis Bio - Buntanetap - the share price is down and I wonder why?
Annovis Bio - Buntanetap - the share price is down and I wonder why?
There are conflicting...
Good news from Annovis (for Alzheimer's)
This just in my inbox! Good news for Annovis as it will give them time on Parkinsons!
"Dear...
Related Posts
“Annovis Bio delivers candor on its Parkinson’s study, even if it doesn’t inspire much confidence”- Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
Anxious to hear any updates from Annovis Bio Butanetap phase 3 trial cohorts
Buntanetap for Mental Illnesses?- Does it indicate failure of another clinical trial
